In the present study, contrary to what was observed with placebo, the AT1R blocker decreased the RBF in response to MS, which, in turn, decreased the SR, implying a potential protective effect of interruption of the AT1R pathway. The gene discussed is AGTR1; the disease is myeloid sarcoma.